Outset Medical to Present at RBC Global Healthcare Conference
Rhea-AI Summary
Outset Medical (Nasdaq: OM) announced that its management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 10:30 a.m. ET.
A live and archived webcast will be accessible via the Investors section of the Outset Medical website.
Positive
- None.
Negative
- None.
News Market Reaction – OM
In the May 12 session, OM gained 5.21%, reflecting a notable positive market reaction. Argus tracked a peak move of +13.8% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Earnings date notice | Neutral | -2.0% | Announced Q1 2026 results date and conference call logistics. |
| Apr 08 | Inducement grants | Neutral | +2.9% | Reported RSU inducement awards for two new hires under Nasdaq rules. |
| Apr 06 | Executive hire | Positive | +0.5% | Named new EVP of Commercial to lead acute, post‑acute and home care teams. |
| Feb 11 | Earnings results | Positive | -16.3% | Reported Q4/FY25 growth, margin expansion, FDA clearance and 2026 guidance. |
| Jan 27 | FDA clearance | Positive | +14.3% | Announced FDA 510(k) clearance for next‑generation Tablo hemodialysis system. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions mostly aligned with sentiment, with one notable selloff on broadly positive earnings and guidance.
Over the last six months, OM has issued updates on leadership, equity inducement grants, earnings, and its next‑generation Tablo platform. FDA clearance on Jan 27 drove a 14.29% gain, while positive Q4/FY25 results on Feb 11 saw a 16.3% decline, showing occasional disconnect between fundamentals and price. More routine items like management changes and an earnings date produced modest, directionally consistent moves. Today’s conference participation fits within this cadence of regular investor communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced that members of management will participate at the RBC Capital Markets Global Health Care conference on Tuesday, May 19, 2026, at 10:30 a.m. Eastern time.
The live and archived webcast of the session will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.
Contact
Investors@outsetmedical.com
